Buprenorphine: New tricks with an old molecule for pain management

Clinical Journal of Pain

Volumn 24, Issue 2, 2008, Pages 93-97

  Heit, Howard A ^a   Gourlay, Douglas L ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Acute pain; Addiction; Chronic pain; S L buphrenorphine

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; OPIATE; OXYCODONE; PERCOCET;

ADULT; ANALGESIA; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; MORPHINE ADDICTION; OFF LABEL DRUG USE; OPIATE ADDICTION; PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR BLOCKING; SHOULDER PAIN;

ACUTE DISEASE; ADMINISTRATION, SUBLINGUAL; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PAIN, INTRACTABLE; RECEPTORS, OPIOID;

EID: 38549096021     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31815ca2b4     Document Type: Article

References (42)

1. Physicians' Disk Reference. Montvale, NJ: Thompson PDR; 2007:2717-2721.
2. Heel RC, Brogden RN, Speight TM, et al. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1979;17:81-110.
3. Martin W, Eades C, Thompson J, et al. The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197:517-532.
4. Richards M, Sadeé W. Buprenorphine is an antagonist at the kappa opioid receptor. Pharm Res. 1985;2:178-181.
5. Richards M, Sadeé W. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in the rate brain as determined by an ex vivo labeling method. Eur J Pharmacol. 1985;114:343-353.
6. Leander J. Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol. 1988;151:457-461.
7. Reisine J, Bell G. Molecular biology of opioid receptors. Trends Neurosci. 1993;16:506-510.
8. Sadeé W, Rosenbaum J, Herz A. Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther. 1982;223:157-162.
9. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985;57:192-196.
10. Tyers MB. A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol. 1980;69:503-512.
11. Tigerstedt I, Tammisto T. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain. Acta Anaesthesiol Scand. 1980;24:462-468.
12. Wang RI, Johnson RP, Robinson N, et al. The study of analgesics following single and repeated doses. J Clin Pharmacol. 1981;21:121-125.
13. Cowan A, Lewis J, MacFarlane I. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. 1977;60:537-545.
14. Budd K. High dose buprenorphine for postoperative analgesia. Anaesthesia. 1981;36:900-903.
15. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18:S3-S13.
16. Clark NC, Lintzeris N, Muhleisen PJ. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Med J Aust. 2002;176:166-167.
17. Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med. 2004;43:580-584.
18. Raisch DW, Fye CL, Boardman KD, et al. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002;36:312-321.
19. Breen CL, Harris SJ, Lintzeris N, et al. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend. 2003;71:49-55.
20. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29:297-326.
21. Bullingham RE, McQuay HJ, Moore RA. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin Pharmacokinet. 1983;8:332-343.
22. Mendelson J, Upton RA, Everhart ET, et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37:31-37.
23. Ling W, Smith D. Buprenorphine: blending practice and research. J Subst Abuse Treat. 2002;23:87-92.
24. Ohtani M, Kotaki H, Nishitateno K, et al. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite norbuprenorphine. J Pharmacol Exp Ther. 1997;281:428-433.
25. Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995;272:505-510.
26. Bridge TP, Fudala PJ, Herbert S, et al. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 2003;70(2 suppl):S79-S85.
27. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70:S39-S47.
28. United States Department of Health and Human Services, SAMHSA. Drug Addiction Treatment Act of 2000 (DATA). Accessed June 3, 2007. Available at: http://buprenorphine.samhsa.gov/fulllaw.html
29. Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry. 1997;41:1095-1101.
30. Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther. 2002;303:695-703.
31. Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berlin). 1999;141:37-46.
32. Heit HA, Covington E, Good PM. Dear DEA. Pain Med. 2004;5:303-308.
33. McNicholas L. Clinical guidelines for the use of buphrenorphine in the treatment of opioid addiction. A Treatment Improvement Protocol, TIP 40:74-76. Available at: http://www.buprenorphine.samhsa.gov./Bup%20Guidelines.pdf.
34. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107-112.
35. Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17:70-83.
36. Heit HA, Gourlay D. Urine drug testing in pain medicine. J Pain Sympt Manage. 2004;27:260-267.
37. Gourlay D, Heit HA, Caplan Y, et al. Urine Drug Testing in Clinical Practice, Dispelling the Myths & Designing Strategies. California Academy of Family Practice. Available at: http://www.familydocs.org/assets/171_UDT%202006. pdf). 3rd ed. November 2006.
38. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol. 1983;13:180-185.
39. Mauro VF, Bonfiglio MF, Spunt AL. Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia. Clin Pharm. 1986;5:837-839.
40. Gourlay DL, Heit HA. Pain and addiction: managing risk through comprehensive care. J Addict Dis. Accepted for publication.
41. Fiellin D, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. NEJM. 2002;347:817-823.
42. Fishman SM, Wilsey B, Mahajan G, et al. Methadone reincarnated: novel clinical applications with related concerns. Pain Med. 2002;3:339-348.